skip to Main Content

3rd Annual Risk Management and Pharmacovigilance America Summit

23 -25 October 2018, Boston

The 3rd Annual Risk Management and Pharmacovigilance America Summit will be held in Boston this coming October and as every year, it will create great atmosphere for PV professionals to network and discuss current issues in the drug safety world. You will hear about all the necessary topics related to the new updates in regulatory, new techniques in digital pharmacovigilance, real examples of automation in PV, how to build a new PV department, Reference Safety Information (RSI) requirements, challenges in adverse events reporting, developing a PV audit strategy, and many more. Do not forget to highlight the dates 23 – 25 October in your calendar and prepare yourself for 3 days full of great presentations, discussions and networking. We are looking forward to meeting you in the best Pharmacovigilance and Risk Management Summit soon!

Request Full Programme

 SUMMIT WILL HOST SPEAKERS FROM THE WORLD’S LEADING COMPANIES

See Sample of Key Note Speakers and Their Case Studies.

Andrea
BEST

Executive Medical Director, Pharmacovigilance and Patient Safety

Kevin
LEARY

Director, Clinical Safety and Risk Management

David
CHONZI

Vice President- Head of Patient Safety and Pharmacovigilance

Bruno
MENDEZ

Global Head Quality Pharmacovigilance

Sandra
RAFF

Senior Director, Global Drug Safety

Anand ANANTHAKRISHNAN

Director, PV Safety System and Operations

EXPERIENCE BASED CASE STUDIES

Immune-Related Adverse Events in oncology: Challenges in Detection, Surveillance and Risk Communication

The challenges of integrating safety data from traditional sources and new sources of data from big data and from digital medical treatment modalities, and the challenges of presenting and assessing this digital medicine safety data will be discussed.

Shire

Cutting costs with intelligent automation

With a focus on immune checkpoint inhibitors, this presentation will address the challenges associated with detection, surveillance and risk communication associated with immunotherapy in the oncology population.

Merck Research Labs

Pharmacovigilance Business Partner Audit Program

Pharmaceutical companies have thousands of business partners for which in many situations a dedicated Pharmacovigilance agreement has to be in place. But how do we ensure the compliance of the PV agreements?

Sanofi

HOT CONFERENCE TOPICS

Will Be Discussed

  • The interface of digital medicine and drug safety
  • Navigating the complexities of Reference Safety Information (RSI) in the clinical trial setting
  • Immune-Related Adverse Events in oncology
  • Artificial Intelligence and Machine Learning in drug safety
  • How to develop an overall business partner PV audit strategy?
  • New challenges in global safety governance
  • Building a drug safety department
  • Benefit-risk assessment and patient centricity in drug safetyEmerging new technologies in PV

WHAT DELEGATES SAID

About Allan Lloyds Events

FOR MORE INFORMATION REQUEST FULL PROGRAMME

See what keynote speakers will be taking part in the exclusive speaking panel.
Explore what Case Studies will be discussed by our senior corporate speakers

3rd Annual Risk Management and Pharmacovigilance America Summit
will start in
TIME IS RUNNING OUT! DON’T RISK MISSING IT
Back To Top